Kornimate/medical-research-clean huggingface dataset:
immersive virtual reality exergames and office workers' cardiometabolic health

Conditions: Exergaming; Metabolic Syndrome

Summary: the worldwide increasing of prevalence of non-communicable diseases has grown the recognition of necessity for identifying the modifiable risk in preventing and managing these diseases. while, the office worker, as a representative group of physical inactivity, is exposed to risk factor of metabolic syndrome which is considered as the pathway of non-communicable diseases. this study mainly focuses on the purpose of examining the interventional efficacy of at-home immersive virtual reality exergame on several metabolic syndrome biomarkers among office workers. in addition, it purposes to determine the impacts of at-home immersive virtual reality exergame on lifestyle pattern of office workers. a 2-armed, single blinded randomized controlled trial (rct) will be applied to examine the therapeutic effects of at-home immersive virtual reality exergame in this exploratory study. 120 japanese office workers with less than 150 minutes per week of moderate to vigorous sports activities will be recruited by a convenience sample method. they are randomly allocated to two parallel groups, which including an intervention group: 12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of meta quest 2, a control group: 12-week of maintaining regular exercise, eating, and working habits without making significant changes. during this 12-week trial, 3 main follow up steps are included at the timelines of 0 week, 6 weeks, 12 weeks. for each follow up, we will collect three types of variables, including major clinical risk factors of metabolic syndrome, lifestyle pattern factors of metabolic syndrome, and demographics (0 week only). to analysis the variance between intervention group and control group, mixed linear model will be applied to understand the efficacy result of this intervention. the variances of metabolic syndrome clinical risk factors between groups would be used to express the therapeutic effects of at-home immersive virtual reality exergame. the changes of lifestyle pattern factors would be applied to show the impacts of at-home immersive virtual reality exergame on lifestyle pattern.


Eligibility criteria:
inclusion criteria: * 18-64 years old * capable of standing and exercising. * having no history of diagnosis of heart disease, cancer, or dementia. * being interested in playing with the exergames. * willingness of adhering to a 12-week interventional exergame treatment. exclusion criteria: * individuals who are already engaged in more than 150 minutes per week of moderate to vigorous activities. * individuals with some pharmacological treatments, some surgery (bariatric surgery), and some traditional chinese medicine.

Keywords: immersive virtual reality physical activity office workers
the effects of a probiotic fermented milk on functional constipation in adults

Conditions: Constipation

Summary: the purpose of this study is to determine the effects of daily consumption for 4 weeks of a fermented milk drink containing a live probiotic microorganism, lactobacillus casei strain shirota (lcs) compared to a placebo without lcs, among adults with functional constipation.


Eligibility criteria:
inclusion criteria: * diagnosed with functional constipation based on rome ii criteria * has a constipation severity score (chinese constipation questionnaire or ccq score) of at least 5, which is the cut-off point for constipated subjects (chan et al, 2005) * free of any cardiovascular related diseases, diabetes, cancer, neurological diseases or any other serious illness, not physically or mentally handicapped * living in klang valley, with no pre-determined plans to be out of town for one week or longer during scheduled intervention period exclusion criteria: * body mass index of less than 16, or 30 and above * pregnant * regular ingestion of probiotic products within the preceding four weeks * regular use of laxatives (average once a week or more) * intake of anticholinergics medications or medications against diarrhea or antibiotics in the preceding 1 month * persons with milk protein allergy * persons with constipation of organic or neurological origin based on health screening * persons with alarm features as assessed by physician during health screening

Keywords: functional constipation probiotic probiotic microorganism lactobacillus casei shirota (lcs)
matching assessment and treatment for children with disruptive behaviour and their parents

Conditions: Disruptive Behavior Disorder; Emotional Disorder; Behavioural Disorder; Attention Deficit Hyperactivity Disorder; Conduct Disorder; Oppositional Defiant Disorder

Summary: this study will develop and test whether personalized profiles of children with disruptive behaviour disorder (dbd) and their parents based on important psychological, emotional, and neuropsychological indicators predict their response to child cognitive behavioral treatment and behavioral parent training.

to accomplish these goals, the investigators will collect psychological, emotional, and neuropsychological measures before and following cognitive behavioural therapy (cbt) for both children and parents. the investigators will use statistical modeling to determine profiles of parents of children and children aged 6-12 years with dbd based on key domains of mental health, emotion regulation, cognition, and parent-child behaviour, and observe whether these profiles allow the study team to predict which sub-groups of parents and children are most and least likely to benefit from child cbt and behavioural parent training (bpt).

Eligibility criteria:
inclusion criteria: * child is borderline/clinically at risk on the child behaviour checklist (cbcl) or teacher report form (trf) (t-score greater than or equal to 60 on externalizing problems composite scale or a t-score greater than or equal to 65 on the oppositional defiant disorder and/or conduct disorder scales) * child has clinically severe impairment in the interpersonal relations (greater than 3), functioning in schoolwork (greater than 3), or total domains (greater than 15) on the columbia impairment scale. * parent is able and willing to participate in a group treatment exclusion criteria: * child has an ongoing query or diagnosis of pervasive developmental disorder or autism or asperger's disorder * evidence of cognitive delays or an intellectual disability (based on the kauffman brief intelligence test-2 (kbit-2), verbal and/or iq composite standard score below 80 or collateral information) * child behaviour or emotional functioning that make group participation not possible * child preference for individual treatment. * parent behaviour or emotional functioning that make group participation not possible * parent preference for individual treatment.

Keywords: emotional and behavioural disorders disruptive behaviour disorder attention deficit hyperactivity disorder conduct disorder oppositional defiant disorder parenting skills behavioural parenting training
safety and efficacy of imm01 plus tislelizumab in patients with advanced solid tumors and lymphomas

Conditions: Solid Tumor; Classic Hodgkin Lymphoma

Summary: this is an open-label, multicenter, phase 1b/2 trial of imm01 (sirpα fc) plus tislelizumab in patients with advanced solid tumors and lymphomas.

this open-label, multicenter, phase 1b/2 trial is conducted to evaluate the safety, tolerability and preliminary activity in patients with advanced solid tumors and lymphomas. this trial includes two parts: the phase 1b dose escalation part and the phase 2 dose expansion part. in the dose escalation part with a standard 3+3 design, imm01 (1.0, 1.5, 2.0 mg/kg) was administered once a week and tislelizumab (200mg) was administered once every 3 weeks. in the dose expansion part, imm01 (the dose determined in the dose escalation part) was administered once a week and tislelizumab (200mg) was administered once every 3 weeks. and the cohorts includes hnscc, nsclc, sclc, r/r chl and others.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, male or female 2. life expectancy≥12 weeks; 3. phase 1b: patients with advanced solid tumors diagnosed by histology or cytology, who have been failure to previous standard treatments; phase 2: patients with hnscc, npc, oc, nsclc, sclc, hcc, chl and other solid tumors diagnosed by histology or cytology, who have been failure to first-line standard treatment (including pd-1/l1) at least; 4. ecog ps of 0 or 1; 5. adequate organs function, including bone marrow, hepatic, renal, cardiac, coagulation. 6. adverse events associated with previous anti-tumor therapy have returned to≤ grade 1(nci ctcae v5.0); exclusion criteria: 1. previous treatment with cd47 inhibitor/sirpαinhibitor or fusion protein; 2. patients with symptomatic or progressive central nervous system (cns) metastasis; 3. uncontrolled hypertension, pulmonary hypertension or unstable angina, myocardial infarction within 6 months prior to administration; a history of chronic heart failure (nyha g3/4); severe arrhythmia; 4. a history of arterial thrombosis, deep venous thrombosis and pulmonary embolism within 3 months prior to administration; 5. a history of moderate or severe dyspnea, interstitial lung disease (ild) or servre pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency; 6. with other malignant tumors; 7. diseases that may cause gastrointestinal bleeding or perforation; 8. uncontrollable pleural, peritoneal or pericardial effusions; 9. a history of immunodeficiency; 10. a history of autoimmune diseases; 11. uncontrolled severe active infections.
occurrence and trend of pregnancies growing outside the womb (ectopic pregnancy) 2009-2018. a study on a defined group of persons

Conditions: Pregnancy, Ectopic

Summary: in this trial researchers want to learn more about the occurrence of pregnancies growing outside the womb over the last decade (2009-2018) and the potential risk factors associated with pregnancies growing outside the womb. electronic data in women who were age 15 to 44 years abstracted from health care systems such as electronic health records (ehr), regional claims systems and administrative databases were used to address research questions on ... * occurrence and trends of pregnancies growing outside the womb; * influence of method of contraception used on occurrence and trends of pregnancies growing outside the womb; * potential risk factors associated with pregnancies growing outside the womb; * trends in management of pregnancies growing outside the womb over the last decade.

the overall goal of this study is to assess the incidence rate of ectopic pregnancy over the last decade in a representative population of us women and potential risk factors associated with ectopic pregnancy.

Eligibility criteria:
inclusion criteria: * women of age 15 to 44 years between 01-jan-2009 and 31-dec-2018 * women enrolled in health plans kaiser permanente northern california (kpnc) and kaiser permanente southern california (kpsc) * women with at least 12 months membership in kpnc and kpsc prior to enrollment

Keywords: ectopic pregnancy electronic medical records chart review intrauterine device (iud)
use of hypoallergenic (h.a.) cereals in children with diagnosed allergy to wheat

Conditions: Food Allergy

Summary: the investigators plan to launch a specific oral tolerance induction (soti) pilot study in order to assess the efficacy and the safety of hypoallergenic (h.a.) wheat cereals, for children with allergy to wheat. the study has the potential to offer a desensitization treatment option for children allergic to wheat. the investigators hypothesize that h.a. wheat cereals have similar efficacy with less side effects than native wheat cereals.

in this pilot study, the investigators aim to assess the feasibility of a soti (specific oral tolerance induction) with hypoallergenic (h.a.) cereals in children with diagnosed ige-mediated allergy to wheat. this is a multi centre, open, pilot study testing 1 product.10 children of any ethnicity aged from 1 to 12 years old with diagnosed allergy to wheat will be eligible to participate in the study. the duration of the treatment will be 6 months with a minimum of 1 month of daily consumption of the hydrolyzed wheat cereals. each subject will feed with a quantity of the assigned study product according to the soti. the soti will be performed at the hospital under the control of qualified doctors and nurses. the study product is administered starting with very low dosages, which are increased stepwise every 30 minutes up to an amount equivalent to the usual daily oral intake. thereafter, the study product corresponding to the maximum dose tolerated is given in a maintenance dose in one serve every day until the final visit during which a challenge test with wheat will be performed to assess the tolerance of whole wheat.

Eligibility criteria:
inclusion criteria: * infant of any ethnicity aged between 1 to 12 years old at the time of enrollment and * positive skin prick test (spt) to wheat and/or positive specific ige to wheat and * immediate positive reaction (ige-type reaction) to wheat as shown by provocation test done a maximum 1 year before the enrollment to the study or an unambiguous history for wheat allergy as evaluated by the investigator and * having obtained his/her signed legal representative's informed consent exclusion criteria: * child on systemic drugs (potentially affecting the allergic reactions e.g. antihistamines) according to half-life at time of enrollment or * congenital illness or malformation that may affect normal growth (especially immunodeficiency) or * child with uncontrolled asthma or * child whose parents/caregivers cannot be expected to comply with treatment or * child currently participating in another interventional clinical trial.

Keywords: soti tolerance desensitization challenge test ha wheat cereals
thrombophilia assessment under doac: effectiveness of activated charcoal

Conditions: Thrombophilia

Summary: direct oral anticoagulants (doac) are anticoagulant molecules that act either directly on factor xa (apixaban, rivaroxaban) or on factor iia (dabigatran). aods interfere with most coagulation tests, especially those performed by chronometric technique. for this reason, part of the thrombophilia workup (protein s, search for lupus anticoagulants, antithrombin for patients on dabigatran) cannot be performed on doacs at the hus. recent studies have highlighted the effectiveness of activated charcoal to adsorb doacs in order to perform certain hemostasis tests.


Eligibility criteria:
inclusion criteria: * adult subject (≥ 18 years of age) * blood sample already analyzed in a usual way in the laboratory as part of the care * subject not objecting to the reuse of his or her medical data for scientific research purposes. exclusion criteria: - insufficient sample

Keywords: thrombophilia direct oral anticoagulants doac apixaban rivaroxaban dabigatran hemostasis tests
observational study of choline, its metabolites, and phospholipids in preterm infants

Conditions: Prematurity

Summary: to study concentrations of choline, its metabolites, and phospholipids in cord blood and remnants of clinically indicated blood samples

to collect cord plasma in preterm and term infants. to collect remnants of clinically indicated blood samples in parturients and hospitalized preterm infants during neonatal intensive care. to determine concentrations of choline, its metabolites, and phospholipids by mass spectrometry. to compare cord plasma concentrations with postnatal plasma concentrations.

Eligibility criteria:
inclusion criteria: * meeting criteria of the 4 cohorts exclusion criteria: * none pre-defined

Keywords: infant, premature infant, newborn choline
prospective randomized trial comparing thd versus stapler operation for 3rd degree hemorrhoids

Conditions: Hemorrhoids

Summary: haemorrhoids have, in literature, extremely high ranges of prevalence, 4,4% to 36% and there is a debate on the best treatment for iii degree hemorrhoids. the stapled hemorrhoidopexy is indicated in grade iii haemorrhoids due to its advantages vs. other techniques in pain reduction and time before resume of normal activity. the new technique of doppler guided trans-anal arterial ligation (thd) appear to be another important therapeutic tool thanks to its scarce complications, the minimally invasive procedure and efficacy of the short term results. the rationale of the two surgical techniques is different: in fact, the stapled hemorrhoidopexy is based on the hypothesis that the mucosal and sub/mucosal resection and stapling can cure the prolapse, etiologic factor of haemorrhoids; on the other hand, the interruption of the arterial inflow of hemorrhoids by thd reduces hemorrhoidal tissue." aim of this study is to compare 2 techniques: the doppler guided transanal haemorrhoidal dearterialisation with the thd device and the stapled haemorrhoidopexy (according to longo) for iii degree (goligher) haemorrhoid, not regarding the number of prolapsed piles

after informed consent 284 patients with iii degree hemorrhoids from 10 colorectal units will be randomized into two groups: stapler vs doppler guided transanal hemorrhoidal dearterialisation with the thd device.the early and long term outcome, as well as other secondary outcomes (costs, return to work and degree of satisfaction) will be recorded and compared.

Eligibility criteria:
inclusion criteria: * iii degree hemorrhoids * both sex * age between 18 and 70 years * ability to understand the procedure * written informed consent exclusion criteria: * previous surgery for hemorrhoids * fecal incontinence * obstructed defecation * other active anorectic diseases * irritable bowel syndrome

Keywords: hemorrhoids stapler doppler artery ligation outcome recurrence
petacc-8 mir-31-3p and mir-31-5p ancillary study

Conditions: Colorectal Cancer

Summary: this is a prospective-retrospective study to determine if the expression of the mirna's mir-31-3p and mir-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-egfr therapy in stage iii colon cancer. the present study will utilize ffpe tumor samples collected from patients enrolled in the petacc-8 study conducted by the fédération francophone de cancérologie digestive (ffcd). this phase 3 clinical trial prospectively randomized fully resected stage iii colon cancer patients to receive adjuvant treatment with either folfox-4 plus cetuximab or flofox-4 alone.


Eligibility criteria:
inclusion criteria: * patient included in petacc08 study * signed informed consent for translational study * ffpe tumor sample available for mir-31-3p and mir-31-5p expression testing exclusion criteria: * patient who have withdrawn their consent for petacc08 and/or for petacc08 translational study
comparison dw-mri vs fdg pet/ct in the detection of early recurrence of cervical well-differentiated thyroid carcinoma

Conditions: Thyroid Cancer; Relapse

Summary: the purpose of the study is to evaluate the concordance between the 18f-pet/ct under thyrotropin stimulation and the diffusion-weighted magnetic resonance imaging, in the detection of residual mass in 40 patients with partial response or relapsed differentiated thyroid carcinoma.

the schedule and the procedures of the study are the following ones : * baseline evaluation : * clinical examination with neck echography after rhtsh stimulation * normal whole body scan * first visit (inclusion): 18f-fdg pet/ct dw-mri of the neck if possible performed shortly after the pet ct or within following days * following visits: at 6 months and 12 months * dw-mri of the neck performed shortly after the pet ct or within following days. * ultrasonography guided fine needle aspiration for cytology for detection of cervical metastases and identifying thyroglobuline in the needle washout fluid if needed and in case of positivity of either pet or dw-mri exams. * histological assessment of biopsies if performed

Eligibility criteria:
inclusion criteria: * male or female, * subjects must be 18 years of age or older, * histologically confirmed papillary or follicular differentiated thyroid carcinoma with partial response or complete response, defined by * thyroglobulin \> 2 μg/l under thyrotrophin stimulation, four months after at least two 131-i based treatments (3,7 gbq/100mci or more if optimal conditions), * negative extension assessment (total body bone scan, (3,7 gbq/100 mci or more)), echography, ct scan ( neck, thorax, abdomen): no findings.. * patient's informed consent form signed. exclusion criteria: * history of previous cancer within the least three years, * performance status \> 2, * protected adults * any medical, psychological, social or disabling conditions that could interfere or jeopardize the patient's participation * history of allergy to radio-iodine, * estimated gfr \< 45 ml/min /m² (mdrd method), * women of childbearing potential without contraceptive method, * uncontrolled diabetes mellitus, * hypersensitivity to fdg or to any radio-tracers, * contraindication to administration of thyrogen® 0.9mg * intraocular foreign bodies or any metallic foreign bodies that contraindicates the mri. * vascular clips, any object or implanted device that could interact with the ferromagnetic field, * coronary and peripheral clips, aortic stent grafts, prosthetic heart valves, annuloplasty rings, vena cava filters, cardiac pacemaker, implantable cardiovascular defibrillators...., * implanted insulin infuser * neurostimulator device * claustrophobia * agitation or psychological trouble

Keywords: recurrence thyroid cancer 18f-fdg pet-ct diffusion-weighted magnetic resonance imaging
radiographic changes and clinical implications of implantation of shortened uncemented femoral stems in tha

Conditions: Aseptic; Osteonecrosis; Hip Osteoarthritis

Summary: the hip prosthesis market is constantly growing with the number of prostheses reaching 949,000 in 2019. along with this, there is also an increase in interest in short stems also called shortened stems. thus on pubmed, in 5 years, 171 publications have been listed. thus, it seems interesting to study and analyze the performance of the shortened stem used in the department of orthopedic surgery and traumatology of the university hospitals of strasbourg and to compare them with the results of the literature.

the objective of this study is to observe the appearance of shortened stem radiological abnormalities at least 2 years postoperatively.

Eligibility criteria:
inclusion criteria: * male or female (age ≥18 years old) * subject operated for first-line tha for an indication of centric hip osteoarthritis (including minor dysplasia and coxa profunda) and aseptic osteonecrosis of the femoral head * subject who received a tha between january 2015 and december 2019 * subject who received an uncemented shortened scc or scla femoral stem * radiological data available: pre-operative, immediate post-operative and post-operative at a minimum of 2 years (≥24 months) * subject not objecting to the reuse of their data for scientific research purposes. exclusion criteria: * subject having expressed its opposition to the reuse of its data for scientific research purposes. * patient operated for inflammatory pathology or major dysplasia, recovery * associated fractures or sequelae of fractures * patient having presented intraoperative or early complications such as infections, intraoperative fracture, dislocation of the hip following the installation of the tha * revision of hip arthroplasty during the study follow-up period for a cause not studied in the study.

Keywords: hip osteoarthritis aseptic; osteonecrosis coxarthrosis avascular necrosis of the femoral head